Literature DB >> 1703959

T helper cell epitope of rabies virus nucleoprotein defined by tri- and tetrapeptides.

H C Ertl1, B Dietzschold, L Otvos.   

Abstract

T cell clones and subsequently hybridomas were generated from rabies virus-immune C3H/He mice to an immunodominant epitope of the viral nucleoprotein, termed 31D, that had previously been identified by a 15-amino acid-long synthetic peptide. T cells to this epitope that by phenotypical and functional characteristics belonged to the T helper cell subset were shown to respond to most rabies and rabies-related viruses. In order to define the minimal sequence needed to elicit a response from 31D-specific T cell clones or hybridomas, a number of peptides of varied lengths, i.e. 3-32 amino acids long, were tested. The ability of the peptides to induce a response was inversely correlated in their lengths, i.e., short peptides (3-5 amino acids long) had to be used at 10(6) times higher concentrations as compared to long peptides (15 or 32 amino acids long). Conversely, the specificity of the T cell response was directly correlated to the length of the peptides, i.e., while the response to 15-amino acid-long peptides exhibited a high degree of specificity, the response to 3- to 5-amino acid-long peptides showed a high degree of flexibility. The long as well as the short peptides had to be presented in association with I-Ek. We speculate that in this system the T cell receptor interacts predominantly with a peptide-induced modification of the I-Ek molecule.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1703959     DOI: 10.1002/eji.1830210102

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  7 in total

1.  Posttranslational side chain modification of a viral epitope results in diminished recognition by specific T cells.

Authors:  J K Larson; L Otvos; H C Ertl
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

2.  Fine specificity and cross-clade reactivity of HIV type 1 Gag-specific CD4+ T cells.

Authors:  Philip J Norris; Howell F Moffett; Christian Brander; Todd M Allen; Kristin M O'Sullivan; Lisa A Cosimi; Daniel E Kaufmann; Bruce D Walker; Eric S Rosenberg
Journal:  AIDS Res Hum Retroviruses       Date:  2004-03       Impact factor: 2.205

3.  Identification of an immunodominant epitope within the phosphoprotein of rabies virus that is recognized by both class I- and class II-restricted T cells.

Authors:  J K Larson; W H Wunner; L Otvos; H C Ertl
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

4.  Lagos bat virus in Kenya.

Authors:  Ivan V Kuzmin; Michael Niezgoda; Richard Franka; Bernard Agwanda; Wanda Markotter; Janet C Beagley; Olga Y Urazova; Robert F Breiman; Charles E Rupprecht
Journal:  J Clin Microbiol       Date:  2008-02-27       Impact factor: 5.948

5.  Rabies virus glycoprotein as a carrier for anthrax protective antigen.

Authors:  Mary Ellen Smith; Martin Koser; Sa Xiao; Catherine Siler; James P McGettigan; Catherine Calkins; Roger J Pomerantz; Bernhard Dietzschold; Matthias J Schnell
Journal:  Virology       Date:  2006-07-03       Impact factor: 3.616

6.  Current challenges in peptide-based drug discovery.

Authors:  Laszlo Otvos; John D Wade
Journal:  Front Chem       Date:  2014-08-08       Impact factor: 5.221

7.  A next generation vaccine against human rabies based on a single dose of a chimpanzee adenovirus vector serotype C.

Authors:  Federico Napolitano; Rossella Merone; Adele Abbate; Virginia Ammendola; Emma Horncastle; Francesca Lanzaro; Marialuisa Esposito; Alessandra Maria Contino; Roberta Sbrocchi; Andrea Sommella; Joshua D Duncan; Jospeh Hinds; Richard A Urbanowicz; Armin Lahm; Stefano Colloca; Antonella Folgori; Jonathan K Ball; Alfredo Nicosia; Benjamin Wizel; Stefania Capone; Alessandra Vitelli
Journal:  PLoS Negl Trop Dis       Date:  2020-07-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.